Healthcare Industry News: Indevus Pharmaceuticals
News Release - June 21, 2007
Elusys Names Jeremy D. Middleton Vice President of Corporate DevelopmentPINE BROOK, N.J., June 21 (HSMN NewsFeed) -- Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company developing antibody-based therapies for the treatment of life-threatening infectious diseases, today announced it has expanded its senior management team with the appointment of Jeremy D. Middleton as Vice President of Corporate Development.
Mr. Middleton added, "Elusys has partnered with MedImmune and Pfizer on collaborative research and license agreements. Partnering with two of the world's top biotech and pharmaceutical companies is a real validation of Elusys' HP Antibody(TM) technology and the company as a whole. HP Antibodies are truly a novel approach to treating a wide variety of serious infectious diseases and there are numerous commercial opportunities for this unique platform."
Mr. Middleton is a biopharmaceutical executive with more than 20 years international experience. Prior to joining Elusys, he was Vice President of Business Development at Valera Pharmaceuticals, Inc., before its merger with Indevus Pharmaceuticals, Inc. During his tenure with Valera, he was responsible for developing corporate strategies to identify and access new market opportunities. Mr. Middleton also played a lead role in negotiating the recent merger with Indevus.
Mr. Middleton was previously a Vice President at Neose Technologies, Inc., a clinical-stage biopharmaceutical company focused on the development of next-generation therapeutic proteins. At Neose, he directed business strategy, commercial development, manufacturing and facilities functions. Formerly, he was Global Product Director for Immunology at Abbott Laboratories/BASF Pharma. Mr. Middleton earned his Bachelor of Science in Applied Chemistry from De Montfort University, Leicester, England.
About Elusys' HP Antibody(TM) Technology
HP Antibodies represent a new approach for the treatment of antibiotic resistant infections distinct from traditional antibody therapy. HP Antibodies utilize natural immune system mechanisms to clear pathogens and provide a means to develop novel drug candidates targeted against bacterial, viral and fungal infections. By targeting a unique immune receptor, HP Antibodies enhance a natural clearance mechanism and direct the rapid removal of pathogens from the circulation to tissue macrophages.
Elusys is a privately-held biopharmaceutical company focused on the development of antibody-based therapeutics for the treatment of life-threatening infectious disease. In March of 2007, the company's anthrax antibody therapeutic, Anthim(TM), was selected to R&D Directions' list of "100 Great Investigational Drugs."
Current venture investors include Essex Woodlands Health Ventures LLC, Invesco Private Capital, Crescendo Ventures, MedImmune Ventures and Pfizer. For more information please visit www.elusys.com.
Source: Elusys Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.